# Coya Therapeutics, Inc. (COYA) · Edgar & Edgarette company card

> Coya Therapeutics (COYA) grew revenue 124% in FY2025 to $8 million, operating margin -284% against a -3.8% median for pharmaceutical preparations, equity 86.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1835022 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/COYA) · [JSON](https://www.pops4.com/boards/company/COYA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $8M |
| Revenue growth, 1 year | 123.6% |
| Revenue growth per year | — |
| Operating margin | -283.9% (prior year -485.4%) |
| Net margin | -267.1% |
| Operating cash flow | −$11M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $47M |
| Long-term debt | — |
| Total assets | $50M |
| Total equity | $43M |
| Equity ÷ assets | 86.1% |
| Return on equity | -49.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 5.24 (safe zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -283.9% in FY2025; revenue is hard to predict: its 80% range is ±28%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $7.9M (FY2025). Experience: revenue up 123.6% on the year; operating margin -283.9%, up from -485.4%. Soundness: equity 86.1% of assets, return on equity -49.3%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $13.0M and $23.4M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -283.9% against a -3.8% median; growth 123.6% against 13.7%.

Range logged 2026-09-20, receipt fa4b5dee227433d9, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-04-02 ([filing](https://www.sec.gov/Archives/edgar/data/1835022/000119312526139094/0001193125-26-139094-index.htm))

## Recent filings

- 8-K · filed 2026-10-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1835022/000119312526421066/0001193125-26-421066-index.htm)
- 8-K · filed 2026-10-05 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1835022/000119312526413218/0001193125-26-413218-index.htm)
- 8-K · filed 2026-09-15 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1835022/000119312526391378/0001193125-26-391378-index.htm)
- 10-Q · filed 2026-08-11 · [filing](https://www.sec.gov/Archives/edgar/data/1835022/000119312526343481/0001193125-26-343481-index.htm)
- 8-K · filed 2026-08-11 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/0001193125-26-343473-index.htm)
- 8-K · filed 2026-06-25 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1835022/000119312526282989/0001193125-26-282989-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001835022.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1835022

## Cite

POPS4, Edgar & Edgarette: Coya Therapeutics, Inc. (COYA) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/COYA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.